

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

In re Entresto (Sacubitril/Valsartan) Patent
Litigation

C.A. No. 20-md-2930-RGA

NOVARTIS PHARMACEUTICALS
CORPORATION,

Plaintiff,

v.

C.A. No. 19-2053-RGA

MSN PHARMACEUTICALS INC., MSN
LABORATORIES PRIVATE
LIMITED, MSN LIFE SCIENCES
PRIVATE LIMITED,

Defendants.

NOTICE OF APPEAL

Notice is hereby given that Plaintiff Novartis Pharmaceuticals Corporation appeals to the United States Court of Appeals for the Federal Circuit from the August 12, 2024 denial of Novartis's Motion for a Rule 62(d) Injunction Pending Appeal and Temporary Restraining Order Pending Resolution of this Motion (D.I. 1457 in 20-md-2930 RGA; D.I. 433 in 19-2053-RGA), and from all orders, opinions, decisions, and rulings prior to the entry of the order that merge therein. Payment of the required fees is provided with this notice. This case is currently pending on appeal to the Federal Circuit (and is fully briefed and awaiting argument) as Federal Circuit Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221. Novartis files this notice to comply with today's order from this Court.

Date: August 12, 2024

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

Alexandra M. Joyce (#6423)

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, Delaware 19801

(302) 984-6300

dsilver@mccarter.com

ajoyce@mccarter.com

OF COUNSEL:

Nicholas N. Kallas

Christina Schwarz

Christopher E. Loh

Jared L. Stringham

VENABLE LLP

151 West 42nd Street

New York, New York 10036

(212) 307-5500

nkallas@venable.com

cschwarz@venable.com

cloh@venable.com

jlstringham@venable.com

*Attorneys for Plaintiff Novartis
Pharmaceuticals Corporation*